Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Lymphoid 3Breast 3Sarcoma 2Other hematologic neoplasm 2Head & Neck 2Genitourinary 2Other solid neoplasm 1Other neoplasm 1Myeloid 1Dermatologic 1

Conditions

Neoplasm Metastasis 1Melanoma 1

Interventions

pembrolizumab 58Cyclophosphamide 53Ipilimumab 52Nivolumab 44aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 18dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11Filgrastim 10Dacarbazine 10spartalizumab 9cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Valproic Acid × Dermatologic × Clear all
NCT00358319 2013-11-25

Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Terminated
42 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡